Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A

[1]  A. Weissman,et al.  Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication , 2017, Proceedings of the National Academy of Sciences.

[2]  Suzanne R. Kalb,et al.  Engineering Botulinum Neurotoxin C1 as a Molecular Vehicle for Intra-Neuronal Drug Delivery , 2017, Scientific Reports.

[3]  Leonard A. Smith,et al.  A matrix-focused structure-activity and binding site flexibility study of quinolinol inhibitors of botulinum neurotoxin serotype A. , 2017, Bioorganic & medicinal chemistry letters.

[4]  P. T. Bremer,et al.  Newly Designed Quinolinol Inhibitors Mitigate the Effects of Botulinum Neurotoxin A in Enzymatic, Cell-Based, and ex Vivo Assays. , 2017, Journal of medicinal chemistry.

[5]  S. Bavari,et al.  Searching for Therapeutics Against Botulinum Neurotoxins: A True Challenge for Drug Discovery. , 2016, Current topics in medicinal chemistry.

[6]  S. Swaminathan,et al.  Interactions of a potent cyclic peptide inhibitor with the light chain of botulinum neurotoxin A: Insights from X-ray crystallography. , 2015, Bioorganic & medicinal chemistry.

[7]  R. Kostrzewa,et al.  Botulinum neurotoxin: Progress in negating its neurotoxicity; and in extending its therapeutic utility via molecular engineering. MiniReview , 2015, Peptides.

[8]  Leonard A. Smith,et al.  Ex vivo inhibition of Clostridium botulinum neurotoxin types B, C, E, and F by small molecular weight inhibitors. , 2015, Toxicon : official journal of the International Society on Toxinology.

[9]  K. Janda,et al.  Toward the discovery of dual inhibitors for botulinum neurotoxin A: concomitant targeting of endocytosis and light chain protease activity. , 2015, Chemical communications.

[10]  K. Janda,et al.  Probing BoNT/A Protease Exosites: Implications for Inhibitor Design and Light Chain Longevity , 2014, Biochemistry.

[11]  C. Montecucco,et al.  Botulinum neurotoxins: genetic, structural and mechanistic insights , 2014, Nature Reviews Microbiology.

[12]  J. Winther,et al.  Quantification of thiols and disulfides. , 2014, Biochimica et biophysica acta.

[13]  Dongbin Zhao,et al.  High throughput screening of disulfide‐containing proteins in a complex mixture , 2013, Proteomics.

[14]  Leonard A. Smith,et al.  The C Terminus of the Catalytic Domain of Type A Botulinum Neurotoxin May Facilitate Product Release from the Active Site* , 2013, The Journal of Biological Chemistry.

[15]  L. Simpson.  The life history of a botulinum toxin molecule. , 2013, Toxicon : official journal of the International Society on Toxinology.

[16]  C. Montecucco,et al.  Botulinum Neurotoxin Type A is Internalized and Translocated from Small Synaptic Vesicles at the Neuromuscular Junction , 2013, Molecular Neurobiology.

[17]  Kim D Janda,et al.  Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: synthesis, crystallography, modeling, kinetic and cellular based studies. , 2013, Bioorganic & medicinal chemistry.

[18]  Matthew A. Lardy,et al.  The C-terminus of Botulinum A Protease Has Profound and Unanticipated Kinetic Consequences Upon the Catalytic Cleft. , 2013, ACS medicinal chemistry letters.

[19]  J. Le,et al.  Foodborne Botulism Treated with Heptavalent Botulism Antitoxin , 2013, The Annals of pharmacotherapy.

[20]  Edwin R. Chapman,et al.  All three components of the neuronal SNARE complex contribute to secretory vesicle docking , 2012, The Journal of cell biology.

[21]  P. Leeson,et al.  Drug discovery: Chemical beauty contest , 2012, Nature.

[22]  E. Duysen,et al.  Role of Acetylcholinesterase on the Structure and Function of Cholinergic Synapses: Insights Gained from Studies on Knockout Mice , 2011, Cellular and Molecular Neurobiology.

[23]  M. Adler,et al.  Detection of six serotypes of botulinum neurotoxin using fluorogenic reporters. , 2011, Analytical biochemistry.

[24]  G. Oyler,et al.  Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. , 2010, Toxicon : official journal of the International Society on Toxinology.

[25]  P. Wipf,et al.  Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A , 2010, PloS one.

[26]  K. Janda,et al.  Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease. , 2010, ACS medicinal chemistry letters.

[27]  Yuan-Ping Pang,et al.  Potent New Small-Molecule Inhibitor of Botulinum Neurotoxin Serotype A Endopeptidase Developed by Synthesis-Based Computer-Aided Molecular Design , 2009, PloS one.

[28]  Shuang Wang,et al.  Neutralizing Antibodies of Botulinum Neurotoxin Serotype A Screened from a Fully Synthetic Human Antibody Phage Display Library , 2009, Journal of biomolecular screening.

[29]  J. Marks,et al.  Antibody Protection against Botulinum Neurotoxin Intoxication in Mice , 2009, Infection and Immunity.

[30]  Leonard A. Smith,et al.  Identification and Biochemical Characterization of Small-Molecule Inhibitors of Clostridium botulinum Neurotoxin Serotype A , 2009, Antimicrobial Agents and Chemotherapy.

[31]  M. Cook,et al.  Egg yolk antibodies for detection and neutralization of Clostridium botulinum type A neurotoxin. , 2009, Journal of food protection.

[32]  Regina Z. Cer,et al.  IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding , 2009, Nucleic Acids Res..

[33]  R. Stein,et al.  Botulinum neurotoxin serotype A inhibitors: small-molecule mercaptoacetamide analogs. , 2009, Bioorganic & medicinal chemistry.

[34]  P. Wipf,et al.  Three‐Dimensional Database Mining Identifies a Unique Chemotype that Unites Structurally Diverse Botulinum Neurotoxin Serotype A Inhibitors in a Three‐Zone Pharmacophore , 2008, ChemMedChem.

[35]  Karen N. Allen,et al.  Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex. , 2008, Biochemistry.

[36]  B. Racette,et al.  Iatrogenic botulism due to therapeutic botulinum toxin a injection in a pediatric patient. , 2007, Clinical neuropharmacology.

[37]  Kim D Janda,et al.  Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility. , 2007, Chemistry & biology.

[38]  J. Barbieri,et al.  Mechanism of Substrate Recognition by Botulinum Neurotoxin Serotype A* , 2007, Journal of Biological Chemistry.

[39]  S. Cai,et al.  Strategies to design inhibitors of Clostridium botulinum neurotoxins. , 2007, Infectious disorders drug targets.

[40]  Andrea M. Stahl,et al.  Inhibition of Metalloprotease Botulinum Serotype A from a Pseudo-peptide Binding Mode to a Small Molecule That Is Active in Primary Neurons* , 2007, Journal of Biological Chemistry.

[41]  S. Gad,et al.  Nonclinical Vehicle Use in Studies by Multiple Routes in Multiple Species , 2006, International journal of toxicology.

[42]  S. Joshi,et al.  An Initial Assessment of the Systemic Pharmacokinetics of Botulinum Toxin , 2006, Journal of Pharmacology and Experimental Therapeutics.

[43]  Lisa M Eubanks,et al.  Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. , 2006, Chemical communications.

[44]  Jay Painter,et al.  Electronic Reprint Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion , 2005 .

[45]  Y. Pang,et al.  Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A. , 2006, Bioorganic & medicinal chemistry.

[46]  S. K. Sharma,et al.  Clostridium botulinum: A Bug with Beauty and Weapon , 2005, Critical reviews in microbiology.

[47]  Axel T. Brunger,et al.  Substrate recognition strategy for botulinum neurotoxin serotype A , 2004, Nature.

[48]  Eric A. Johnson,et al.  The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability. , 2004, Protein expression and purification.

[49]  David C. Richardson,et al.  MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes , 2004, Nucleic Acids Res..

[50]  B. Rupp,et al.  Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[51]  L. Simpson,et al.  Identification of the major steps in botulinum toxin action. , 2004, Annual review of pharmacology and toxicology.

[52]  Dagmar Ringe,et al.  POVScript+: a program for model and data visualization using persistence of vision ray-tracing , 2003 .

[53]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination , 2022 .

[54]  B. Roques,et al.  High-throughput fluorogenic assay for determination of botulinum type B neurotoxin protease activity. , 2001, Analytical biochemistry.

[55]  M. Adler,et al.  Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. , 2001, Toxicon : official journal of the International Society on Toxinology.

[56]  K. Bhatia,et al.  Uses of botulinum toxin injection in medicine today , 2000, BMJ : British Medical Journal.

[57]  M. Adler,et al.  Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity , 1998, FEBS letters.

[58]  A. Ferrer-Montiel,et al.  Tyrosine Phosphorylation Modulates the Activity of Clostridial Neurotoxins* , 1996, The Journal of Biological Chemistry.

[59]  A. Corwin,et al.  Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  M. Adler,et al.  Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin. , 1996, Toxicon : official journal of the International Society on Toxinology.

[61]  F. Benfenati,et al.  Tetanus and Botulinum Neurotoxins Are Zinc Proteases Specific for Components of the Neuroexocytosis Apparatus a , 1994, Annals of the New York Academy of Sciences.

[62]  Thomas C. Südhof,et al.  Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25 , 1993, Nature.

[63]  G. Schiavo,et al.  Botulinum neurotoxins are zinc proteins. , 1992, The Journal of biological chemistry.

[64]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[65]  P. Chakrabarti,et al.  Geometry of interaction of metal ions with sulfur-containing ligands in protein structures. , 1989, Biochemistry.

[66]  V. Sathyamoorthy,et al.  Role of the heavy and light chains of botulinum neurotoxin in neuromuscular paralysis. , 1987, The Journal of biological chemistry.

[67]  H. Sugiyama,et al.  Role of a Protease in Natural Activation of Clostridium botulinum Neurotoxin , 1972, Infection and immunity.

[68]  G. Oyler,et al.  Prevention and Treatment of Botulism , 2014 .

[69]  G. Oyler,et al.  Persistence of Botulinum neurotoxin inactivation of nerve function. , 2013, Current topics in microbiology and immunology.

[70]  L. Tauc,et al.  Clues to the multi-phasic inhibitory action of botulinum neurotoxins on release of transmitters. , 1990, Journal de physiologie.

[71]  S. Skaper,et al.  A procedure for purifying neuron-like cells in cultures from central nervous tissue with a defined medium. , 1979, Developmental neuroscience.